The Peptide AppContributors188 articles
Co-founder and author
Junaid “Jay” Spall
Jay is a chemist, biochemist and entrepreneur whose work connects scientific research with consumer health products. He has held Chief Science Officer and product development leadership roles and previously served as Chief Revenue Officer at Minicircle.
As a co-founder of The Peptide App, Jay focuses on clinical research, real-world data and clearer peptide education. He has spoken at California Peptide Club gatherings in San Francisco and Austin about international regulation, clinical trials and consumer quality assurance.
Recent podcasts
On FrequencyThe science of healing trauma, weight loss and longevity, 1 hr 18 min
The Dr. Joy Kong PodcastFollistatin gene therapy results, 47 min
Ever Forward RadioFollistatin therapy for VO2 max, HRV and longevity, 1 hr 27 min
Joe Naz PodcastExploring human genetic enhancement, 2 hr 18 min
Mike TorchiaNew focus technology: innovating your tomorrow, 43 min
Articles by Jay Spall
BPC-157 and TB-5009
- BPC-157 has 100-plus studies, nearly all from one Zagreb groupThe Zagreb group behind most BPC-157 papers reports gut, tendon and vascular effects in animals. Independent replication by other labs is scarce.
- BPC-157 healed rat injuries when given orally or by systemic injectionBPC-157 improved healing in rats by intraperitoneal shot, in drinking water or as a topical cream. No human study has compared routes or injection sites.
- BPC-157 healed tendons in rats; human data are three small pilotsBPC-157 improved strength and collagen organization in cut rat Achilles tendons in a 2003 study. Human data are three small pilots, none in tendon patients.
- BPC-157's half-life is under 30 minutes in rats and dogsBPC-157's elimination half-life is under 30 minutes in rats and dogs, the only species measured. The 4 to 6 hour figure online doesn't trace to a study.
- BPC-157's rat results came mostly from oral and intraperitoneal dosingBPC-157 rodent studies mostly used oral or intraperitoneal dosing, not subcutaneous injection, so they do not establish the injectable protocol clinics sell.
- Oral BPC-157 was tested against induced gut injury in ratsIn rat studies, BPC-157 dissolved in drinking water was tested against induced gut injury. No study has measured its absorption in people or set a dose.
- TB-500 is a fragment of thymosin beta-4, the protein tested in trialsTB-500 is a short synthetic fragment, not full-length thymosin beta-4. Every human trial in this family tested the 43-amino-acid protein, not the fragment.
- TB-500 matched full-length thymosin beta-4's wound repair in miceTB-500 matched full-length thymosin beta-4 in angiogenesis assays and mouse wound repair. No human trial has tested the fragment itself.
- WADA bans BPC-157 and TB-500 as non-approved substancesWADA bans BPC-157 and TB-500 because neither is approved for human use anywhere. The ban is a regulatory category, not a finding that they enhance performance.
Blends and compatibility2
- Peptide blends lock all component doses togetherA peptide blend vial holds its components at a fixed ratio, so changing the draw volume changes every peptide dose by the same proportion.
- Peptide mixing requires four separate compatibility checksMixing two peptides in one vial requires checking reactivity, pH, degradation rates, and dosing math. No stability data exist for any specific combination.
Combinations and evidence14
- CJC-1295 raised GH 2- to 10-fold; synergy studies used other peptidesOne CJC-1295 injection raised mean GH 2- to 10-fold in a placebo-controlled trial. Synergy studies paired GHRH with other secretagogues, never ipamorelin.
- Drug combinations need a four-arm factorial trial to prove synergyDrug combinations need a four-arm factorial trial to isolate a combination effect. Most consumer stacks have never been tested this way, for benefit or harm.
- DSIP sleep stacks rest on mixed DSIP trials and a real GH-sleep linkDSIP's small human sleep trials were inconsistent, though deep sleep and GH release are linked. No published human trial has tested DSIP with a GH secretagogue.
- Each ingredient in a stack needs its own evidence gradeFormal grading finds evidence certainty varies widely between parts of one protocol, so grade each ingredient. The exact combination is rarely tested.
- Longevity stack compounds show uneven results, each tested on its ownNAD+ precursors raised blood NAD+ but left function mostly flat; elamipretide missed both Phase 3 co-primary endpoints. No study has tested any two together.
- Melanotan II and PT-141 act on the same melanocortin receptor familyMelanotan II and PT-141 share melanocortin receptors, so stacking adds agonism rather than a second mechanism. No trial has tested the two together.
- Sermorelin and tesamorelin share a receptor; a stack is a bigger doseSermorelin and tesamorelin activate the same pituitary GHRH receptor, so stacking them acts like a higher single dose. No trial has tested the pair.
- Subcutaneous volume limits depend on site, person, and formulationSome subcutaneous biologics are dosed at 5 to 20 mL, usually by a health professional. The 1 mL rule is a convention, and mixing changes tonicity too.
- TB-500 alone improved rat tendon biomechanics; BPC-157 added nothingTB-500 alone improved repaired rat tendon biomechanics; BPC-157 added nothing measurable. Human data on the pair cover four patients in one uncontrolled review.
- TB-500's parent protein has stronger human data than GHK-Cu or BPC-157Thymosin beta-4, TB-500's parent protein, has small controlled trials, but none tested the TB-500 fragment. No study has tested all three peptides together.
- The mitochondrial peptide stack is one peptide and two small moleculesMOTS-c has mouse and cell data on insulin sensitivity, and the two small molecules have rodent data. None has a human trial, and no study combines the three.
- Trials back loading for tendons; stacks cite single-agent studiesTwo loading programs improved Achilles pain and function in a 58-patient trial. BPC-157's orthopedic record is 35 preclinical studies and one chart review.
- Two cosmetic peptides combined gave mixed results in a 2017 trialA 2017 trial of argireline plus tripeptide-10 citrulline found an inconsistent pattern against each alone. Larger stacks remain untested against their parts.
- Two interventions that work alone can cancel each other outTwo interventions that each work can blunt or cancel each other via a shared pathway, as trials pairing cold water immersion or ibuprofen with training show.
Compound evidence130
- A bladder extract related to Vesilute cut urge episodes in a trialChitomur, a related bladder extract, cut urge episodes in a small randomized trial. Vesilute itself has never been tested in a controlled study.
- ACE-031 grew muscle in women; nosebleeds halted its Duchenne trialOne dose of ACE-031 raised lean mass 3.3% in healthy postmenopausal women. Nosebleeds and dilated skin capillaries in boys halted its Duchenne trial.
- ACE-083 increased muscle volume in FSHD without improving strengthACE-083 increased muscle volume 9.5% to 16.4% versus placebo in a Phase 2 FSHD trial. Strength and functional tests did not improve.
- Adipotide cut fat in animals but kidney injury ended its human trialAdipotide shrank fat in mice and monkeys by destroying its blood supply. Kidney injury tracked the fat-loss doses in monkeys and ended the one human trial.
- Afamelanotide implants, approved for EPP, extended pain-free sun timeThe FDA-approved afamelanotide implant gave people with EPP more pain-free sun time in two Phase 3 trials. No controlled trial covers tanning or libido.
- Anamorelin increases lean mass but not grip strength in cachexiaAnamorelin raised lean mass in three Phase 3 cancer cachexia trials and is approved in Japan. Grip strength did not improve, and the FDA and EMA rejected it.
- AOD-9604 was safe across six trials but missed its weight-loss goalAOD-9604 looked clean on safety in six trials but missed its weight-loss goal in a 536-person pivotal trial. An earlier 12-week signal did not replicate.
- Apelin infusions raise cardiac output; aging claims come from miceApelin infusions raise cardiac output and blood flow in human trials. Apelin's muscle and aging claims come from mice, and no human trial has tested them.
- ARA-290 increased nerve fiber density in two small Phase 2 trialsARA-290 increased nerve fiber density and improved neuropathic symptom scores in small 28-day Phase 2 trials. It is unapproved, with no Phase 3 trial.
- Argireline cream improved wrinkles in a 60-person trialA 10% Argireline cream improved wrinkles versus placebo in a 60-person trial. It acts on SNAP-25 more weakly than Botox, and its skin uptake is unproven.
- BDNF infusions triggered dose-limiting side effects in an ALS trialRecombinant BDNF infused into the spinal fluid of ALS patients caused dose-related side effects that capped the dose. Exercise raises blood BDNF reliably.
- Bronchogen reversed COPD-like lung remodeling in a rat studyBronchogen reversed COPD-like lung remodeling in one rat study and activated bronchial genes in human cell cultures. No human clinical trial has tested it.
- Calcitonin's weak benefit lost to an ambiguous cancer signal in 2012Europe pulled calcitonin's osteoporosis indication in 2012 when an ambiguous cancer signal outweighed a weak fracture benefit. The cancer link is unproven.
- Cardiogen stimulated heart-cell growth in rat tissue studiesCardiogen stimulated heart-cell proliferation in young and aged rat tissue cultures. Every study is preclinical and traces to one research group.
- Cartalax was associated with cartilage gene changes in cell studiesCartalax was associated with changes in cartilage-related genes in cell models. No human trial has tested it, and one lab produced all the research.
- Cerebrolysin improved dementia and stroke recovery scores in IV trialsIV Cerebrolysin improved cognition in dementia and arm recovery after stroke. Cochrane found no acute stroke benefit; no cited trial enrolled healthy adults.
- Chonluten suppressed TNF and IL-6 in a human immune-cell lineChonluten's EDG sequence suppressed TNF and IL-6 in a human monocyte/macrophage cell line. It has no controlled human trial, and lung effects are untested.
- CJC-1295 No DAC amplified growth hormone release in rodentsCJC-1295 No DAC's backbone produced fourfold more GH release than unmodified GRF(1-29) in rats. All three published human studies used the DAC version.
- Cortagen sped sciatic nerve regrowth by 27% in injured ratsCortagen sped sciatic nerve regrowth by 27% and nerve conduction by 40% in injured rats. No study has measured cortisol, and none has tested it in humans.
- Cortexin shrank brain necrosis in rat models of brain ischemiaCortexin, an animal brain extract, cut brain necrosis in rat ischemia models. One 80-person trial passed independent review, with modest, low-certainty effects.
- Davunetide missed both main endpoints in a 313-patient PSP trialDavunetide failed a 313-patient PSP trial on both primary endpoints. Its earlier signals were secondary, and brain delivery was never confirmed.
- Dihexa eased memory deficits in rats and in Alzheimer's model miceOral dihexa improved memory in rat and mouse models but failed in a Huntington's rat model. It has no human trials, and its key mechanism paper was retracted.
- DSIP's best human results are in alcohol and opiate withdrawalDSIP showed statistically weak sleep effects in a controlled trial of 16 insomniacs. Its stronger withdrawal signal comes from uncontrolled trials.
- Elevated GDF-15 tracked with higher death risk in three human cohortsChronically high GDF-15 tracks with cardiovascular, cancer, and kidney disease mortality. Drug developers build an antibody to block GDF-15, not to raise it.
- Endomorphin-1 eased pain in mice dosed into the spine or brainEndomorphin-1 eased pain in mice when delivered into the spine or brain. No human trial exists, and no human data show an injected dose reaching the brain.
- Epitalon extended mouse lifespan; most human studies used epithalaminEpitalon extended lifespan in two mouse strains and lengthened telomeres in human cell cultures. Most human data come from epithalamin, a bovine pineal extract.
- Exenatide did not slow Parkinson's in its 96-week Phase 3 trialExenatide did not slow Parkinson's motor decline in a 96-week multicenter Phase 3 trial. The result did not replicate an earlier single-center Phase 2 signal.
- FGF21 analogs show modest benefits for MASH in early trialsFGF21 analogs modestly reduce liver fat and improve fibrosis in Phase 2b MASH trials. No human data support longevity claims or large weight loss.
- FGL produced memory and synaptic gains in three rat studiesFGL produced memory and synaptic gains in three rat studies, including one that used subcutaneous doses. Human data are limited to a single-dose safety study.
- Follistatin-344 gene therapy built muscle in mice and macaquesFollistatin-344 gene therapy built muscle in animals and improved walking in two six-patient open-label trials. Injected FS-344 peptide has no human data.
- FOXO4-DRI cleared senescent cells in aged mice across three studiesFOXO4-DRI cleared senescent cells and improved treadmill performance in aged mice, and two other labs reproduced the clearance. No human trial has tested it.
- Fragment 176-191 cut weight gain and fat mass in obese miceFragment 176-191 cut weight gain and fat mass in obese mice. It has no human trials, and its modified analog AOD9604 missed its weight-loss goal in people.
- GHK shifted gene expression in cultured cells; skin trials were mixedGHK's gene profile in cultured cells opposed a lung-tissue destruction pattern in one computational study. Its human trials are topical, with mixed results.
- GHK-Cu injection bypasses the gut's copper regulationInjected GHK-Cu skips the gut checkpoint that regulates copper absorption, and copper is about 16% of its mass. No study has measured copper levels in users.
- Ghrelin agonists increased food intake 10.2% to 70.1% in human trialsGhrelin receptor agonists raised food intake by 10.2% to 70.1% in human trials of people with an intact vagus nerve. One low-dose infusion found no effect.
- GHRP-2 raised growth hormone about 13-fold in seven healthy menGHRP-2 raised growth hormone in four small human trials, about 13-fold in healthy men. None measured body composition, and the longest adult trial ran 30 days.
- GHRP-6 triggered a GH pulse in men, women and children after one doseA single GHRP-6 dose raised GH in men, women and children in a 37-person trial. No trial has tested weeks of dosing for body composition or recovery.
- Glucose blunts GHRH-driven GH release, giving fasted dosing a basisGlucose blunts GHRH-stimulated growth hormone release, which gives fasted dosing a real basis. The timing windows and dietary fat rules have no such test.
- Gonadorelin by pump induced sperm production in GnRH-deficient menPump-delivered gonadorelin restored sperm production in GnRH-deficient men in trials. The twice-daily shots used alongside TRT have no dedicated trial.
- Growth hormone added lean mass in trials while strength stayed flatGrowth hormone added about 2.1 kg of lean mass in trials of healthy young adults, but strength stayed flat. Scans count the fluid it retains as lean mass.
- hCG alone normalized testosterone in hypogonadotropic menhCG alone normalized testosterone in hypogonadotropic men across four trials, and sperm production began once FSH was added. TRT use is extrapolated.
- Hexarelin raised growth hormone in people and protected rodent heartsIn small 1990s trials, IV hexarelin released about twice GHRH's growth hormone. It protected rat and mouse hearts; no therapeutic human RCT has been completed.
- High-dose injected amycretin beat placebo on weight in a meta-analysisHigh-dose injected amycretin cut weight 23.95 points beyond placebo in a meta-analysis. Its own trials tested safety, and none compared it with semaglutide.
- Higher natural Ac-SDKP tracked with less fibrotic signaling in rodentsACE inhibitors raise natural Ac-SDKP, and higher levels tracked with less fibrotic signaling in rodents. No controlled human trial has tested injecting it.
- Humanin protected cultured neurons and improved memory in aged miceHumanin blocked Alzheimer's-linked cell death in cultured neurons, and its analog HNG reduced heart fibrosis in aged mice. No completed human trial exists.
- IGF-1 DES infusion lifted muscle protein synthesis 21% in ratsIGF-1 DES raised muscle protein synthesis 21% in nitrogen-restricted rats on infusion. No study has tested whether local injection builds new muscle fibers.
- IGF-1 LR3 was 1.5 to 6 times as potent as native IGF-1 in ratsIn rats, IGF-1 LR3 was 1.5 to 6 times as potent as native IGF-1 because it escapes binding proteins. No human trial has set a dose or safety profile.
- In aged mice, GDF-11 improved heart and stroke outcomesGDF-11 reversed cardiac hypertrophy and aided stroke recovery in aged mice. No human trial has reported, and independent labs dispute its muscle results.
- Infused PYY3-36 cut food intake in trials; oral PYY3-36 alone did notInfused PYY3-36 cut food intake by about 30% at a test meal in one trial. Oral PYY3-36 alone did not, and nausea confounds the infusion results.
- Injected abaloparatide cut fractures; its patch lagged on bone densityIn the ACTIVE trial of 2,463 postmenopausal women, injected abaloparatide cut new fractures versus placebo. A patch version missed bone density non-inferiority.
- Injection route matters for peptides, but effects vary by moleculeRoute effects vary by molecule: glucagon peaked higher intramuscularly yet reached similar total exposure. Most peptides people inject lack human route data.
- Intranasal insulin matched placebo on cognition in five pooled trialsIntranasal insulin matched placebo on cognition and daily function across five pooled trials in MCI or Alzheimer's. A device switch clouds the largest trial.
- Intranasal neuropeptide Y was well tolerated in a 26-person PTSD trialIntranasal NPY was well tolerated in a 26-person PTSD trial. Higher doses were linked to a larger anxiety drop than placebo, a single-dose secondary outcome.
- Ipamorelin released GH in men but missed in two bowel-recovery trialsIn rats and swine, ipamorelin released GH without raising cortisol; single doses raised GH in 40 healthy men. Both bowel-recovery trials missed their goals.
- IPP and VPP lowered systolic pressure by 1 to 6 mmHg in meta-analysesIPP and VPP, fermented-milk tripeptides, cut systolic pressure by roughly 1 to 6 mmHg in pooled analyses. Stricter, double-blind trials found smaller effects.
- Irisin is real, but most human studies used kits that missed itIrisin is a real muscle-derived peptide in human blood. The ELISA kits behind most human studies cross-reacted with other proteins instead of detecting it.
- IV and inhaled VIP gave mixed results in three severe COVID-19 trialsIV or inhaled VIP gave mixed results in three trials in COVID-19 respiratory failure, and the largest stopped for futility. None tested mold illness or CIRS.
- Kisspeptin-10 raises LH and testosterone in men in IV studiesIV kisspeptin-10 raised LH and testosterone in healthy men and in men with type 2 diabetes in single research sessions. Daily subcutaneous dosing is untested.
- Klotho extends mouse lifespan; one monkey study reported memory gainsKlotho overexpression extends mouse lifespan, and one monkey study reported memory gains. That study is unreplicated, and no human klotho therapy exists.
- KPV curbed inflammation in rodent colitis and peritonitis modelsKPV reduced inflammation in rodent colitis and peritonitis models from two research groups. No human trial exists, and oral uptake in people is unestablished.
- KTTKS moisturizer reduced wrinkles in a 93-person, 12-week trialA 3 ppm KTTKS moisturizer reduced wrinkles versus placebo in a 93-person, 12-week split-face trial. No large independent trial has replicated it.
- Lactoferrin's sepsis benefit in preterm infants shrank as trials grewLactoferrin modestly cut late-onset sepsis in preterm infants, but less so as trials grew. Newer pooled data show no significant NEC or mortality benefit.
- Larazotide eased celiac symptoms but missed its permeability endpointLarazotide reduced gluten-triggered symptoms in four celiac trials. It missed its permeability endpoint in the larger ones, and Phase 3 was halted in 2022.
- Leptin treats lipodystrophy but barely moved weight in common obesityLeptin therapy works in lipodystrophy, where the body makes almost no leptin. In common obesity, where levels run high, injections gave no reliable weight loss.
- Linaclotide works as a pill because its receptor faces into the gutLinaclotide acts on receptors facing the inside of the gut, so it never needs absorption. Trials show strong constipation benefit and weaker pain evidence.
- Liraglutide cut cardiovascular death 22% in type 2 diabetes (LEADER)In LEADER, liraglutide cut cardiovascular death 22% in 9,340 adults with type 2 diabetes at high risk. The trial enrolled only people with diabetes.
- Livagen's developers report restored liver function in animal modelsLivagen's developers report it restored liver function in animal injury models and loosened chromatin in cultured blood cells. No human trial exists.
- Longevity peptide claims rest on cell, biomarker and pilot studiesLongevity peptide claims draw on cell studies, biomarkers and small pilots. The NIA program that tested 54 agents in over 30,000 mice has run none of them.
- Macimorelin is FDA-approved as a one-dose test for adult GH deficiencyMacimorelin is FDA-approved as a single-dose oral test for adult growth hormone deficiency. Repeated dosing for muscle, fat loss or sleep was never studied.
- Mazdutide cut body weight 14% at 48 weeks in a Chinese phase 3 trialMazdutide produced 14% mean weight loss at 48 weeks in a 610-adult phase 3 trial. Every published trial enrolled Chinese adults, and none ran longer.
- Mecasermin is approved for severe primary IGF-1 deficiency in childrenApproved for severe primary IGF-1 deficiency in children, mecasermin raised height velocity in open-label series. Its safety record does not cover IGF-1 LR3.
- Melanotan II's real risks come from receptor nonselectivityMelanotan II activates melanocortin receptors beyond the skin and, in a case report, altered how moles looked. Whether it raises melanoma rates is unmeasured.
- Melanotan II's receptor promiscuity explains its multiple effectsMelanotan II causes tanning and erections by activating several melanocortin receptors at once. Its human trials, run from 1996 to 2000, enrolled 23 people.
- MGF switched on first in injured rat muscle, the basis for PEG-MGFIn injured rat muscle, MGF switched on first and tracked stem-cell markers. Two cell studies of its E-peptide conflict, and no human trial has tested PEG-MGF.
- MK-677 raised IGF-1 and lean mass, not strength, in a year-long trialMK-677 raised IGF-1 about 40 to 94% in four studies. Strength did not improve, glucose tolerance worsened, and a heart-failure signal halted one trial.
- MOTS-c reversed age-related insulin resistance in miceMOTS-c prevented diet-induced obesity and reversed age-related insulin resistance in mice. Its first controlled human trial opened in 2026 and has not reported.
- N-Acetyl Selank Amidate's evidence all comes from unmodified SelankEvery study cited for N-Acetyl Selank Amidate tested unmodified Selank, including two small Russian anxiety trials. The modified form has no studies of its own.
- Nasal orexin-A changed REM sleep and smell in small narcolepsy trialsIntranasal orexin-A changes REM sleep, smell and sympathetic activity in small human trials. No trial has tested it for alertness during sleep loss.
- Nasal oxytocin matched placebo on sexual function in three trialsNasal oxytocin did no better than placebo for sexual desire, arousal or function in three trials. One couples trial found a modest rise in orgasm intensity.
- Nasal peptides can reach the brain via two narrow neural pathwaysNasal peptides can reach the brain along olfactory and trigeminal nerves, but slowly. Oxytocin took up to 75 minutes to rise in human cerebrospinal fluid.
- One 266-person elderly trial linked Thymalin to halved mortalityThymalin was linked to 2-fold lower all-cause mortality over 6 to 8 years in a 266-person elderly trial. One Russian group ran it; no one has replicated it.
- One CJC-1295 with DAC injection kept GH elevated for at least 6 daysOne CJC-1295 with DAC injection raised GH 2-10 fold for at least 6 days in healthy volunteers. No published trial has measured fat loss, lean mass or recovery.
- Oral glutathione lightened sun-exposed skin modestly in small trialsOral glutathione modestly reduced melanin in small, short trials, mostly on sun-exposed skin. IV glutathione lacks supporting trial evidence.
- Oral glutathione raised blood levels in some trials but not othersOral glutathione raised blood levels 30-35% in a 6-month trial but not in a 4-week one. IV glutathione's best trial protected against cisplatin neuropathy.
- Osteocalcin reliably marks bone formation; hormone claims are disputedOsteocalcin is a well-validated bone formation marker. Its hormone role rests on one lab's mouse knockouts, which two independent labs did not reproduce.
- Ovagen, marketed for fertility, eased kidney injury in ratsOvagen protected rat kidneys from gentamicin and ischemic injury and raised MMP-14 in aging kidney cells. No study involves ovarian tissue, fertility or people.
- Oxyntomodulin with GLP-1 and peptide YY cut weight in a 4-week trialOxyntomodulin with GLP-1 and peptide YY cut weight 4.4 kg vs 2.5 kg on saline over four weeks. Every cited trial relied on infusion or supervised injections.
- P21 improved memory in normal, aged and Alzheimer's-model rodentsP21 improved memory and neurogenesis in four rodent studies. No human trial has tested P21, and no safe or effective human dose has been established.
- Pancragen lowered glucose in diabetic rats and aged monkeysPancragen lowered glucose in diabetic rats and aged monkeys, and glucose improved in a 33-patient open-label pilot. All five papers come from one Russian group.
- PE-22-28 blocks TREK-1 and showed antidepressant-like effects in micePE-22-28 blocks the TREK-1 potassium channel and does not mimic BDNF. All of its evidence is preclinical, and no human trial or safety data exist.
- Pentadeca Arginate is the same peptide as BPC-157 in a different saltPentadeca Arginate is BPC-157 with an arginate salt instead of acetate. No study has tested PDA itself, and BPC-157's own human data are minimal.
- Peptide blends lock together doses of ingredients with uneven evidenceGHK-Cu has mixed human trials and KPV has rodent colitis data, and a blend locks their doses together. No study has tested the full mix or its stability.
- Peptide cycling is a convention borrowed from steroid and SARM culturePeptide cycling began in steroid culture, and daily MK-677 kept IGF-1 up in older adults for two years. Popular peptides have no cycled-versus-continuous trial.
- Pexiganan matched ofloxacin in pooled data but missed approval twicePexiganan cream matched oral ofloxacin for mildly infected diabetic foot ulcers in pooled trial data. Neither of its two Phase 3 programs supported approval.
- Pinealon preserved dendritic spines in Alzheimer's-model micePinealon preserved dendritic spines in Alzheimer's-model mice and lowered reactive oxygen species in cell studies. No randomized human trial exists.
- Pramlintide produced real but modest weight loss in obesity trialsPramlintide produced real but modest weight loss: 5.6-6.8% beyond placebo at 12 months. Newer weekly amylin analogs are not a clean test of the same mechanism.
- Prostamax reduced inflammation in rats with induced prostatitisProstamax, the peptide KEDP, reduced inflammation in rats with induced prostatitis and altered chromatin in cultured human lymphocytes. No human trial exists.
- PT-141 modestly raised desire in premenopausal women with HSDDBremelanotide (PT-141) modestly raises desire in premenopausal women with HSDD. Efficacy in men is unproven, and nausea hit 40% in the extension trial.
- Secretin matched placebo for autism in a Cochrane review of 16 trialsSecretin did no better than placebo on core autism symptoms in Cochrane reviews of 14 and 16 trials. Its US approval is for diagnostic testing only.
- Selank and Semax are unrelated peptides, each studied on its ownSelank rivaled a benzodiazepine in a 62-patient Russian trial, while Semax's nootropic case rests on mechanism. No study has tested the two together.
- Selank matched a benzodiazepine for anxiety in a 62-patient trialSelank matched the benzodiazepine medazepam on anxiety scales in a 62-patient Russian trial. The trial had no placebo arm and has no international replication.
- Semax sped neurological recovery in open-label Russian stroke trialsSemax sped neurological recovery in open-label Russian stroke trials. Its one healthy-adult study enrolled 20 men with no placebo arm or blinding.
- Serelaxin lowered organ-injury markers but not deaths in RELAX-AHF-2Serelaxin's 180-day cardiovascular death rate was 8.7% versus 8.9% on placebo in RELAX-AHF-2. The earlier 37% mortality drop was a secondary RELAX-AHF finding.
- Sermorelin raised GH and cognitive scores in trials of older adultsSermorelin raised GH in older adults and improved cognition in an 89-person, six-month trial. The trials had no fat-loss endpoint, and today's doses are lower.
- Setmelanotide is approved for confirmed genetic obesity syndromesSetmelanotide produced 10% or more weight loss in most POMC-deficient and about a third of Bardet-Biedl patients. Its trials did not test common obesity.
- SHLP2's evidence is cell and rodent work, separate from MOTS-c'sSHLP2's proposed mitochondrial role rests on cell and rodent work. MOTS-c findings do not transfer, and no study has tested SHLP2 in humans.
- Snap-8 mimics part of SNAP-25, the protein Botox cutsSnap-8 copies a SNAP-25 fragment, with mechanism data borrowed from Argireline. Its 30-60% wrinkle figure comes from unreviewed industry data.
- SS-31 won FDA approval for Barth syndrome; its myopathy Phase 3 missedAn elamipretide (SS-31) formulation won accelerated FDA approval for Barth syndrome in 2025. A 218-person Phase 3 in mitochondrial myopathy missed both goals.
- Survodutide cut body weight 13% versus 5.4% on placebo in phase 3Survodutide cut body weight 13.0% versus 5.4% on placebo in a 76-week phase 3 trial. It is unapproved and not proven superior to other GLP-1 drugs.
- Swallowed peptides rarely survive; oral semaglutide is an exceptionSwallowed peptides face stomach enzymes, intestinal enzymes, and gut-wall and liver barriers. Oral semaglutide is the clearest documented exception.
- Teduglutide grows gut lining in short bowel syndrome, its approved useTeduglutide grows intestinal lining and cuts IV nutrition needs in short bowel syndrome trials. No trial has tested it for leaky gut or IBS.
- Teriparatide prevents fractures in osteoporosis; healing data are thinTeriparatide cut new vertebral fractures to 5.4%, versus 12.0% on risedronate, in a 24-month trial. Faster healing of an existing break is not established.
- Tesamorelin cut visceral fat in HIV; sermorelin has smaller trialsTesamorelin cut visceral fat 10.9% versus 0.6% on placebo in a Phase 3 HIV trial. Sermorelin shares its receptor but has smaller trials, mostly in children.
- Tesamorelin improved cognition in a 20-week trial of 152 older adultsTesamorelin improved executive function in a randomized trial of 152 adults aged 55 to 87. The gain was modest and partly faded after a 10-week washout.
- Tesamorelin shrinks visceral fat in people with HIV lipodystrophyTesamorelin cut visceral fat 10% to 18% in HIV-associated lipodystrophy trials. The effect is unproven in healthy adults with normal GH function.
- Testagen's open-label prostatitis study reported a testosterone riseIn 36 men with prostatitis and androgen deficiency, an open-label study reported a testosterone rise on add-on Testagen. It had no placebo arm or randomization.
- Thymogen shifted immune markers in lab work and small Russian trialsThymogen shifted immune markers in lab studies and small Russian trials, and lowered tumor rates in one rat study. No independent blinded trial has tested it.
- Thymopentin's best trial result was fewer myasthenia gravis relapsesThymopentin lowered relapses in a 135-patient myasthenia gravis trial. In HIV and hepatitis B vaccine trials, gains appeared only in subgroups.
- Thymosin Alpha-1 beat interferon in hepatitis B; sepsis data are mixedThymosin Alpha-1 beat interferon-alpha on virologic response in a 4-trial hepatitis B meta-analysis. Its largest sepsis trial found no 28-day mortality benefit.
- Thymosin Beta-4 sped rat wound healing; human trials were topicalThymosin Beta-4 sped skin wound healing in rats, and its eye-drop and ulcer trials gave mixed results. No human trial has tested it for tendon injury.
- Thymulin needs zinc to act, and it curbed inflammation in miceZinc switches thymulin on, and the hormone curbed inflammation in mouse studies. Its cited human data are one 1982 case series in three children.
- Thymulin prolonged the growth phase of cultured human hair folliclesThymulin at 10 pg/mL prolonged the growth phase of human scalp follicles in organ culture. That one study is unreplicated, and no controlled hair trial exists.
- Topical GHK-Cu closed diabetic ulcers faster in a 40-patient trialTopical GHK-Cu gel closed diabetic ulcers faster than vehicle in a 40-patient trial. Injectable GHK-Cu has no published human trial.
- Topical LL-37 aided ulcer healing in small trials; the largest missedTopical LL-37 aided healing of leg and foot ulcers in two small trials. The largest, a 148-patient Phase IIb trial, missed its primary endpoint.
- Topical PTD-DBM regrew hair in mice by easing a brake on Wnt signalingTopical PTD-DBM regrew hair and spurred new follicles in healing mouse skin. All three primary studies come from one Yonsei group, and no human trial exists.
- TRH produces rapid mood improvement in trials but fades quicklyIntravenous and intrathecal TRH cut depression scores within hours in small controlled trials. The lift lasted up to 48 hours before fading.
- Trofinetide's Rett syndrome benefit is modest and diarrhea is commonTrofinetide, FDA-approved for Rett syndrome, modestly beat placebo on communication in a 187-patient Phase 3 trial. Diarrhea hit 75-80% of trial patients.
- Vesugen's open-label study in 41 men reported better penile blood flowAn open-label study in 41 elderly men with vasculogenic ED reported better penile blood flow on Vesugen. Its anti-aging claims rest on cell and animal data.
- Vilon extended lifespan in two of three studies in tumor-prone miceVilon extended lifespan in two studies of tumor-prone female CBA mice, and a third found no significant survival gain. Its human data come from cells in a dish.
- Vosoritide sped growth 1.6 cm/year in children with achondroplasiaVosoritide at 15 µg/kg raised growth velocity 1.6 cm/year over placebo in a Phase 3 trial in children with achondroplasia. Final adult height is unmeasured.
GLP-1 and metabolic peptides12
- About 15% of weight lost in GLP-1 drug trials is skeletal muscleAbout 15% of the weight lost in GLP-1 drug trials is skeletal muscle on CT or MRI, and about 25% is fat-free mass. The typical trial was small and short.
- Cagrilintide cut weight up to 10.8% alone and 20.4% with semaglutideCagrilintide cut weight up to 10.8% alone in phase 2 and 20.4% with semaglutide in REDEFINE 1. All five trials were funded by Novo Nordisk.
- GLP-1 drugs and GH secretagogues move blood sugar in opposite waysAn oral ghrelin mimetic raised fasting glucose over two years in healthy older adults, while GLP-1 drugs lower it. No published trial has combined the two.
- GLP-1 medications work best titrated slowly, with other drugs adjustedGLP-1 medications work best on a slow dose ramp, with insulin and blood pressure pills adjusted as weight falls. Faster escalation adds harm, not weight loss.
- Lifting and protein preserved lean mass in calorie-deficit trialsResistance training and protein above the RDA preserve lean mass during a deficit in trials. Popular T3, clenbuterol and SARM stacks lack that evidence.
- Oral semaglutide is about 1% absorbed, so tablet doses run highOral semaglutide reaches the blood at about 1% bioavailability through the absorption enhancer SNAC, so tablets need 3 to 14 mg. PIONEER trials show it works.
- Retatrutide cut weight up to 17.5% in Phase 2; MOTS-c is preclinicalRetatrutide cut weight up to 17.5% at 24 weeks in a Phase 2 trial, while native MOTS-c was studied in mice and cells. No study has tested the two together.
- Retatrutide's top dose cut weight 24.2% in a Phase 2 trialRetatrutide's top dose cut weight 24.2% versus 2.1% on placebo in Phase 2. It is investigational, with no published head-to-head trial against tirzepatide.
- Semaglutide reduced weight and cardiovascular events in three trialsSemaglutide cut weight 14.9% versus 2.4% on placebo in STEP 1 and reduced cardiovascular events in SUSTAIN-6 and SELECT. Substantial regain follows stopping.
- Slower titration eased GLP-1 nausea; BPC-157's gut data come from ratsSlower titration reduced GLP-1 side effects in trials, and BPC-157's gut data come from rodent injury models. No trial has tested BPC-157 with a GLP-1 drug.
- Stopping a GLP-1 brings back about 60% of lost weight within a yearAbout 60 percent of lost weight returns within a year of stopping a GLP-1, and insulin and blood pressure drugs need revisiting. No taper has been tested.
- Tirzepatide 15 mg cut weight 20.9% and beat semaglutide head to headTirzepatide cut weight a mean 20.9% at 15 mg versus 3.1% on placebo in SURMOUNT-1 and beat semaglutide head to head. The trials give no controlled regain data.
Handling and product records9
- Blunt needles core vial stoppers far more often than sharp onesBlunt plastic needles cored 40.8% of vial stoppers versus 4.2% for sharp needles in one study. The data come from anesthesia practice, not peptide vials.
- Dilute peptides lose more to vial and syringe surfacesPeptides bind to glass and plastic, so dilute solutions lose a larger share of the dose. The data come from insulin bags and colistin labware, not home vials.
- FSH absorbed alike from muscle and under the skin in a 19-woman trialIn a randomized crossover trial, FSH reached matching peak, timing and total exposure by intramuscular and subcutaneous injection. Most peptides lack such data.
- Needle length determines injection depth, not gaugeNeedle length, not gauge, decides which tissue layer an injection reaches. Gauge measures tube diameter and has small, inconsistent effects on pain.
- Needles in household trash endanger waste handlers more than injectorsNeedles in household trash mainly endanger waste handlers. Safe disposal needs a rigid, puncture-resistant, closable container and a local pathway.
- Peptides that won't dissolve need a pH shift first, not more waterPeptide solubility can drop sharply near the isoelectric pH, where net charge nears zero. Dissolving in mild acid or base before diluting is the standard fix.
- Poor site rotation is the top risk factor for insulin injection lumpsLipohypertrophy affects about 42% to 59% of long-term insulin users, and poor rotation is its top risk factor. The data come from insulin, not other peptides.
- Subcutaneous air bubbles threaten your dose, not your lifeSubcutaneous air bubbles don't cause fatal embolism; they sit in tissue, not veins. The real risk is underdosing: the bubble displaces drug in the syringe.
- Two peptides that dissolve together still belong in separate vialsDissolving together is the easy question; separate vials remain the reversible, checkable default. Stability data for the pairings people mix are unpublished.
Reconstitution and syringe math5
- Mcg/mg mix-ups cause thousandfold errors; a volume check catches themConfusing mcg and mg shifts a dose 1,000-fold, typically during reconstitution math. An independent check of drawn volume against vial content catches it.
- Peptide reconstitution volume should put your dose mid-syringeReconstitution volume changes peptide concentration, not the amount in the vial. Pick a volume that puts your dose mid-barrel to reduce measurement error.
- Syringe dead space can waste up to a third of a small doseSyringe dead space can waste up to a third of a 0.2 mL dose. Fixed-needle, low dead space syringes cut that waste without any change in injection technique.
- Syringe units measure volume, not doseA unit on a U-100 syringe marks 0.01 mL of volume, whatever is dissolved in it. Your dose depends on the concentration you create when reconstituting.
- U-40 and U-100 syringe mix-ups cause 2.5-fold dosing errorsU-40 and U-100 syringes space unit marks for different concentrations, so the wrong one causes a 2.5-fold dosing error. Any dilution means redoing the math.
Storage and handling7
- Freeze-dried peptides tolerate shipping far better than dissolved onesFreeze-dried peptides tolerate shipping because a dry, glassy state slows most degradation. Labels set the rules; Cetrotide's dry powder must be refrigerated.
- Gentle swirling dissolves peptide powder; shaking whips in airShaking makes large proteins unfold and clump at the air-water surface. Lab tests skipped short peptides, which have little folded structure to lose.
- Hour for hour, heat spikes outweigh mild warmth in shelf-life mathMean kinetic temperature, the accepted excursion math, weights spikes far above mild warmth. It needs stability data that gray-market sellers rarely publish.
- Peptide degradation depends on water, time and sequence, not just heatPeptides degrade mainly through deamidation and oxidation, water-dependent reactions set by sequence. Time in solution and pH matter alongside temperature.
- Peptide gels in the vial come from self-assembly, not chemical damagePeptide gelling in the vial is a physical rearrangement of intact chains, not chemical damage. No PubMed study shows that AOD-9604 or kisspeptin-10 gels.
- Peptide light damage depends on sequence and sustained exposureLight damage concentrates in peptides with tryptophan, tyrosine, phenylalanine, cysteine, or methionine. In one protein study, damage came from weeks of light.
- Vial cloudiness has at least four causes; two are quality failuresVial cloudiness can mean air, undissolved solid, aggregation, or contamination, and only some warrant discarding. Clarity proves neither sterility nor potency.